Kidney Function Assessment

  • Rene R. BreaultEmail author


Kidney dysfunction can present acutely due to various injuries or disease processes or can be a progressive condition as a result of other chronic illnesses such as diabetes or hypertension. Pharmacists have an important role to play in evaluating patients’ renal function. Assessing renal function in a systematic way will aid in appropriate dosage adjustment of renally eliminated medications and prevent toxicity and potential further kidney damage. Understanding and interpreting the various markers of kidney function are important to identify patients at risk of kidney disease. This will potentially lead to early disease identification and implementation of appropriate interventions to reduce disease progression and provide ongoing management.


Renal function Acute kidney injury Chronic kidney disease Renal laboratory tests Kidney assessment 


  1. 1.
    The Kidney Foundation of Canada. No Title [Internet]. [cited 2018 Feb 11]. Available from:
  2. 2.
    The National Kidney Foundation. No Title [Internet]. [cited 2018 Feb 11]. Available from:
  3. 3.
    Al Hamarneh YN, Hemmelgarn B, Curtis C, Balint C, Jones CA, Tsuyuki RT. Community pharmacist targeted screening for chronic kidney disease. Can Pharm J (Ott). 2016;149(1):13–7.CrossRefGoogle Scholar
  4. 4.
    Davis EM. Chapter 16. Renal system. In: Jones RM, editor. Patient assessment in pharmacy practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2016. p. 293–307.Google Scholar
  5. 5.
    Stanfield CL. Chapter 18. The urinary system: renal function. In: Stanfield CL, editor. Principles of human physiology. 5th ed. Glenview, IL: Pearson Education Inc.; 2013. p. 503–30.Google Scholar
  6. 6.
    Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefGoogle Scholar
  7. 7.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–70.CrossRefGoogle Scholar
  8. 8.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AR 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefGoogle Scholar
  9. 9.
    KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):4–4.CrossRefGoogle Scholar
  10. 10.
    Kellum J, Lameire N, Aspelin P, Barsoum RS, Burdmann E, Goldstein SL, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.CrossRefGoogle Scholar
  11. 11.
    Khalil P, Murty P, Palevsky PM. The patient with acute kidney injury. Prim Care. 2008;35(2):239–64.CrossRefGoogle Scholar
  12. 12.
    CKD Pathway. No Title [Internet]. [cited 2018 May 25]. Available from:
  13. 13.
    Diabetes Canada Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can Diabetes J. 2018;42(Suppl 1):S1–325.Google Scholar
  14. 14.
    KDIGO. Clinical practice guideline for lipid management in chronic hidney disease. Kidney Int. 2013;3(3):182–9.Google Scholar
  15. 15.
    Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2011;27 Suppl A:S1–59.CrossRefGoogle Scholar
  16. 16.
    Matzke GR, Aronoff GR, Atkinson AJ, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease -- a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–37.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of Alberta, Faculty of Pharmacy and Pharmaceutical SciencesEdmontonCanada

Personalised recommendations